Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00179738 · ClinicalTrials.gov registry record · Phase 2
A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Androgen Independent Prostate Cancer.
A Phase 2 study, sponsored by Celgene Corporation.
- Terminated
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00179738 is a Phase 2 study that was terminated before completion, run by Celgene Corporation. The registered enrollment target is 40 participants.
The verdict
NCT00179738, a Phase 2 study, was terminated before completion, sponsored by Celgene Corporation.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
Subjects who qualify will receive single agent oral lenalidomide daily on days 1-21 every 28 day cycle. Subjects will continue on study until documented disease progression
Interventions
- DRUG CC5013
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2005-04 |
| Est. Completion | 2007-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00179738
The ClinicalTrials.gov registry entry for NCT00179738 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene Corporation, which has 40 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CC5013 is the first listed.
NCT00179738 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00179738 about?
NCT00179738 is a clinical study titled "A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Androgen Independent Prostate Cancer.". Subjects who qualify will receive single agent oral lenalidomide daily on days 1-21 every 28 day cycle. Subjects will continue on study until documented disease progression
What is the current status of trial NCT00179738?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2005-04. Estimated completion is 2007-04.
What interventions are being tested in trial NCT00179738?
The interventions under investigation include: CC5013 (DRUG).
Who is sponsoring clinical trial NCT00179738?
This trial is sponsored by Celgene Corporation, which has 40 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.